Rani Therapeutics Holdings (RANI): Bozor kapitallashuvining daromadga nisbati

ranitherapeutics.com (RANI) brendining ramzi va logotipi

Robotlashtirilgan biologik yetkazib berish bo'yicha noyob patentlar Rani Therapeutics (RANI) uchun kuchli texnologik to'siqni yaratadi. Ushbu narx-savdo ko'rsatkichi grafigi joriy tebranishlarni namoyish etadi, bunda 9.20 belgisi ushbu metrikani aks ettiradi. Aktivning barqarorligi hozirda klinik sinovlar natijalariga bog'liq, biroq RaniPill ning kengayish salohiyati arzon avtomatlashtirilgan kapsula ishlab chiqarish tufayli yuqori marjalarni va'da qilmoqda.

Narxning daromadga nisbati: Rani Therapeutics Inc (RANI) 04.07.2022 - 13.11.2026 uchun

Rani Therapeutics (RANI) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Narxlar dinamikasi grafigi ranitherapeutics.com|RANI - Maqsadli narxlar grafigi
- birja kapitallashuvi ma'lumotlari:
Bozor qiymati Rani Therapeutics Inc|RANI - Korxona qiymati
- balans kapitallashuvi ko'rsatkichlari:
Bitta aksiya hisobiga balans qiymati Rani Therapeutics|RANI - Kompaniyaning balans qiymati|Kapitallashuvning balans qiymatiga nisbati ranitherapeutics.com|RANI - Kompaniyaning umumiy aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Umumiy qarzning kapitalga nisbati koeffitsiyenti Rani Therapeutics|RANI - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati ranitherapeutics.com|RANI - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati Rani Therapeutics Inc|RANI - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli kredit va qarzlari Rani Therapeutics|Shoshilinch likvidlik ranitherapeutics.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
RANI - Kompaniyaning sof foydasi|Kutilayotgan sof daromad Rani Therapeutics|RANI - P/E multiplikatori|Forvard P/E multiplikatori ranitherapeutics.com|RANI - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Rani Therapeutics Inc|RANI - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Rani Therapeutics|RANI - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi ranitherapeutics.com|RANI - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi Rani Therapeutics
- umumiy tushum va sotuv hajmi ma'lumotlari:
RANI - Daromad va sotish hajmi|Kompaniyaning kelajakdagi savdosi ranitherapeutics.com|RANI - P/S multiplikatori|Forvard narx/daromad multiplikatori Rani Therapeutics Inc
Kompaniyaning jamlanma tahliliyoti:Rani Therapeutics Holdings
Rani Therapeutics Holdings, Inc. asosiy tovari

Rani Therapeutics (RANI) robotlashtirilgan kapsulalarning klinik sinovlariga e'tibor qaratadi va hozirda tijorat daromadlarini keltirmayapti. Savdolarning yo'qligi sababli, taxminiy narx-savdo koeffitsiyenti cheksizlikka intiladi, bu esa kelajakdagi muvaffaqiyatlarning spekulyativ bahosini aks ettiradi. Ushbu koeffitsiyent aktivning premiumini aniqlash uchun biznesning bozor qiymatini uning savdo hajmi bilan solishtiradi. Taxminiy narx-savdo koeffitsiyentiga asoslangan tahlil kapitalizatsiya va haqiqiy pul oqimlari o'rtasidagi xavfli tafovutni o'z vaqtida aniqlash imkonini beradi.

Raqobatdosh kompaniyalar

HLN (haleon.com) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Kenvue KVUE|Bozor kapitallashuvining daromadga nisbati VRNA|Jyong Biotech Corp - P/S multiplikatori|LGND - P/S multiplikatori|Amneal Pharmaceuticals (AMRX) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati PRGO|ALVO (Alvotech SA) - P/S multiplikatori|Liquidia Corp (LQDA) - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati GLPG (Galapagos Genomics)|ANIP (ANI Pharmaceuticals Corp) - Bozor kapitallashuvining daromadga nisbati|MannKind Corporation - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati AMPH (amphastar.com)|Pacira BioSciences, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati SPRY (ARS Pharmaceuticals Inc)|TBPH: P/S multiplikatori|Sotuvga nisbatan narx Aquestive Corp (AQST)|Narxning daromadga nisbati scPharmaceuticals, Inc.|TECX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori TNXP|P/S multiplikatori sxtchina.com (SXTC)|Narxning daromadga nisbati Eupraxia Pharmaceuticals Inc. EPRX|BHST (BioHarvest Sciences Inc) - Narxning sotuvga nisbati|eXoZymes Inc - P/S multiplikatori|Sotuvga nisbatan narx Oramed Pharmaceuticals|ENTX (enterabio.com) - Kapitalizatsiyaning daromadga nisbati|MindWalk Holdings, Inc. (HYFT) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati ABVC|CPIX (Cumberland Corp) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori QNTM|Narx/daromad koeffitsiyenti fibrogen.com|P/S multiplikatori TELO (Telomir Pharmaceuticals, Inc.)|SNYR - Kapitalizatsiyaning daromadga nisbati|RLYB - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti Lexaria Bioscience LEXX|Pulmatrix, Inc. (PULM) - Narxning daromadga nisbati|Pheton Holdings - Bozor kapitallashuvining daromadga nisbati|APM (Aptorum Group Ltd) - P/S multiplikatori|P/S multiplikatori Lyra Therapeutics Inc.|Narxning daromadga nisbati Impact BioMedical (IBO)|tnfpharma.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori YCBD (cbdMD)|Narx/daromad koeffitsiyenti painreform.com (PRFX)|CYTO - Narxning daromadga nisbati|Narxning sotuvga nisbati LIPO|OPTN: P/S multiplikatori|Pieris Pharma - Bozor kapitallashuvining daromadga nisbati|PROC (Procaps Group S.A.) - P/S multiplikatori|P/S multiplikatori petrospharma.com|Narxning daromadga nisbati Qilian International Holding (QLI)|SLRN (Acelyrin Inc.) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati TFF Pharma TFFP